CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

EchocardiographyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug798 During COVID-19 Pandemic Wiki 0.71
drug2788 convalescent plasma application to SARS-CoV-2 infected patients Wiki 0.71
drug135 After COVID-19 Pandemic Wiki 0.71
drug2557 Transpulmonary thermodilution Wiki 0.71

Correlated MeSH Terms (10)

Name (Synonyms) Correlation
D018754 Ventricular Dysfunction NIH 0.50
D000075902 Clinical Deterioration NIH 0.50
D018487 Ventricular Dysfunction, Left NIH 0.50
D012769 Shock, NIH 0.29
D055371 Acute Lung Injury NIH 0.07
D012127 Respiratory Distress Syndrome, Newborn NIH 0.07
D012128 Respiratory Distress Syndrome, Adult NIH 0.06
D003141 Communicable Diseases NIH 0.06
D007239 Infection NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Hemodynamic Characteristics of Patients With SARS-CoV-2: PiCCOVID Study

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a public health emergency of international concern. Hospitalized COVID-19-positive patients requiring ICU care is increasing along with the course of epidemic. A large number of these patients developed acute respiratory distress syndrome (ARDS) according to current data. However, the related hemodynamic characteristic has so far been rarely described.

NCT04337983 Coronavirus SARS-CoV-2 COVID-19 Acute Respiratory Distress Syndrome Shock Acute Circulatory Failure Left Ventricular Dysfunction Fluid Overload Device: Transpulmonary thermodilution Device: Echocardiography
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Ventricular Dysfunction Ventricular Dysfunction, Left Shock

Primary Outcomes

Description: Body temperature(°C)

Measure: Body temperature

Time: Through study completion, an estimation of 6 months

Description: Blood pressure in mmHg

Measure: Blood pressure

Time: Through study completion, an estimation of 6 months

Description: Pulse (heart rate) in times/minute

Measure: Pulse (heart rate)

Time: Through study completion, an estimation of 6 months

Description: Respiratory rate in times/minute

Measure: Respiratory rate

Time: Through study completion, an estimation of 6 months

Description: Cardiac index (L/min/m2)

Measure: Data provided by transpulmonary thermodilution-CI

Time: Through study completion, an estimation of 6 months

Description: Global end-diastolic volume(mL/m2)

Measure: Data provided by transpulmonary thermodilution-GEDV

Time: Through study completion, an estimation of 6 months

Description: Extravascular lung water (mL/kg)

Measure: Data provided by transpulmonary thermodilution-EVLW

Time: Through study completion, an estimation of 6 months

Description: Pulmonary vascular permeability index

Measure: Data provided by transpulmonary thermodilution-PVPI

Time: Through study completion, an estimation of 6 months

Measure: Incidence of abnormal laboratory test results

Time: Through study completion, an estimation of 6 months

Secondary Outcomes

Description: Left ventricle ejection fraction, Segmental left ventricle contractility, Speckle tracking data of the left and right ventricles, Dimensions of right and left cavities and Diastolic function of left ventricle

Measure: Incidence of new-onset or reversible systolic left ventricular dysfunction

Time: Through study completion, an estimation of 6 months

Description: The worst extravascular lung water

Measure: Changes of extravascular lung water measured by transpulmonary thermodilution

Time: Change from baseline extravascular lung water at 6 months

Description: The worst pulmonary vascular permeability index

Measure: Changes of pulmonary vascular permeability index measured by transpulmonary thermodilution

Time: Change from baseline extravascular lung water at 6 months

Measure: Correlation between the hemodynamic characteristics and 90-day mortality

Time: Up to 90th day after inclusion

2 Cardiac Structural and Functional Characteristics in COVID-19: A Dynamic Echocardiographic Study

The cardiovascular effects of coronavirus disease 2019 (COVID-19) are not yet fully known. We conducted a prospective and dynamic echocardiographic study to investigate the cardiac structural and functional changes in COVID-19 patients in intensive care unit (ICU).

NCT04352842 Covid19 Echocardiography Other: Echocardiography

Primary Outcomes

Description: Death of any cause

Measure: Death

Time: From admission to April 8 2020 (cutoff day)

No related HPO nodes (Using clinical trials)